brimonidine tartrate has been researched along with nimodipine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Grehn, F | 1 |
Agey, P; Dong, CJ; Guo, Y; Hare, WA; Wheeler, L | 1 |
2 other study(ies) available for brimonidine tartrate and nimodipine
Article | Year |
---|---|
[Prospects for neuroprotective glaucoma therapy].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Apoptosis; Betaxolol; Brain-Derived Neurotrophic Factor; Brimonidine Tartrate; Calcium Channel Blockers; Disease Models, Animal; Dopamine Agents; Glaucoma; Glaucoma, Open-Angle; Haplorhini; Humans; Memantine; Neuroprotective Agents; Nimodipine; Nitric Oxide Synthase; Quinoxalines; Receptors, N-Methyl-D-Aspartate | 2001 |
Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Calcium; Calcium Channel Blockers; Excitatory Amino Acid Agonists; Injections; Male; Microscopy, Confocal; N-Methylaspartate; Nimodipine; Patch-Clamp Techniques; Quinoxalines; Rabbits; Rats; Rats, Inbred BN; Receptors, Adrenergic, alpha-2; Receptors, N-Methyl-D-Aspartate; Retinal Diseases; Retinal Ganglion Cells; Vitreous Body | 2010 |